Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cairomycin B, a new antibiotic

I R Shimi, N Abedallah, S Fathy

    Antimicrobial Agents and Chemotherapy
    |March 1, 1977
    PubMed
    Summary
    This summary is machine-generated.

    Cairomycin B, a novel cyclic peptide antibiotic from Streptomyces, shows activity against gram-positive bacteria but exhibits high toxicity and weak serum binding. Further research is needed to assess its therapeutic potential.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Biochemical and virological response (by PCR) to interferon therapy in chronic hepatitis C.

    The Journal of the Egyptian Public Health Association·1997
    Same author

    Mycologic study of tinea capitis in Qatar.

    International journal of dermatology·1991
    Same author

    Hyperkeratosis lenticularis perstans.

    International journal of dermatology·1988
    Same author

    Xeroderma pigmentosum in Qatar.

    Cutis·1986
    Same author

    A new antitumour substance, 7-oxabicyclo (2.2.1)-5-heptene-2,3-dicarboxylic anhydride.

    European journal of cancer & clinical oncology·1982
    Same author

    Nilemycin, an intercalating agent for deoxyribonucleic acid.

    The International journal of biochemistry·1982
    Same journal

    <i>In vitro</i> antibacterial activity of gepotidacin in combination with other antimicrobial agents against <i>Neisseria gonorrhoeae</i> isolates.

    Antimicrobial agents and chemotherapy·2026
    Same journal

    Development of domain-specific probes of <i>Plasmodium falciparum</i> heat shock protein 70-1.

    Antimicrobial agents and chemotherapy·2026
    Same journal

    Addressing therapeutic options for KPC-3-producing ST307-<i>Klebsiella pneumoniae</i>: insights from <i>in vitro</i> evolution and mutant prevention strategies.

    Antimicrobial agents and chemotherapy·2026
    Same journal

    Indole-based hybrids target both asexual parasites and gametocytes of <i>Plasmodium falciparum</i> and synergize with lumefantrine.

    Antimicrobial agents and chemotherapy·2026
    Same journal

    Lineage-specific loss of the type VI secretion system in <i>Acinetobacter baumannii</i> ST19 is associated with reduced accessory genome content.

    Antimicrobial agents and chemotherapy·2026
    Same journal

    Genomic diversity and topical antimicrobial resistance in <i>Staphylococcus aureus</i> from clinical and carriage populations in the New York-New Jersey region.

    Antimicrobial agents and chemotherapy·2026
    See all related articles

    Area of Science:

    • Microbiology
    • Natural Product Chemistry
    • Pharmacology

    Background:

    • Discovery of novel antibiotics is crucial to combat rising antimicrobial resistance.
    • Streptomyces species are a prolific source of diverse bioactive compounds.
    • Cyclic peptides represent a promising class of antimicrobial agents.

    Purpose of the Study:

    • To isolate and characterize a new cyclic peptide antibiotic, Cairomycin B.
    • To evaluate the antimicrobial activity and preliminary toxicity of Cairomycin B.
    • To determine the chemical properties and composition of Cairomycin B.

    Main Methods:

    • Isolation of Cairomycin B from Streptomyces As-C-19.
    • Determination of empirical formula (C10H15N3O3) and constituent amino acids (aspartic acid, lysine) via acid hydrolysis.

    Related Experiment Videos

  • Characterization using spectral analysis and chemical properties.
  • Assessment of solubility, melting point, antimicrobial spectrum, toxicity, and serum-binding properties.

    • Main Results:

    • Cairomycin B was successfully isolated and identified as a cyclic peptide.
    • The antibiotic demonstrated activity primarily against gram-positive bacteria.
    • High toxicity in experimental animals and weak serum-binding properties were observed.
    • Specific solubility characteristics were determined.

    Conclusions:

    • Cairomycin B is a novel cyclic peptide antibiotic with selective activity against gram-positive bacteria.
    • Its significant toxicity and weak serum binding may limit its therapeutic applications.
    • Further investigation is warranted to explore structure-activity relationships and potential modifications.